洞悉 投资策略

close

选择一个类别。

• 可持续性
• 金融市场
• 企业家精神
• 生活方式
• 金融知识

The constant rise in cyber-attacks means that robust cybersecurity is no longer a nice-to-have; it's a necessity. This presents growing opportunities for companies in the business of helping organisations to protect themselves.

Steel will remain essential for the transition to a greener future. So decarbonising the manufacturing process of this key material for many renewable energy technologies is vital for reducing CO2 emissions from supply chains.

It's been a strong year for many asset classes globally, as the global economy has demonstrated resilience in the face of continued, if moderate, inflation. Rising geopolitical risks do pose a concern, but strategic fiscal policies and a broadening earnings recovery are creating a positive...

The quick answer is: Yes, but not necessarily in the near-term. Long-term debt sustainability is an issue, and temporary spikes in government bond yields may become more common. But it's not a reason for investors to avoid bonds altogether.

Often, investors who care about sustainability steer clear of high-carbon-emitting companies. But there can be value in investing in firms willing to transform their businesses to make a contribution to decarbonisation.

The inexorable move to digitalisation, driven by technological breakthroughs like artificial intelligence and cloud computing, is propelling investment in the physical infrastructure needed to process and store all the newly created data.

Edge AI will bring a vast array of benefits to consumers and businesses by running artificial intelligence algorithms locally on phones and computers, rather than in the cloud. Among the results: apps with better availability, personalisation, privacy and security.

With monetary policy and inflation moving in the right direction, undervalued smaller companies could benefit from a broad-based economic recovery.

Weight-loss drugs are reducing the risk of obesity-related diseases like diabetes, stroke and hypertension, which is excellent news for patients. But how will this affect the pharma industry's sales of treatments for these conditions?